Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
In relapsed or refractory AML allogeneic HCT is considered to be the only treatment by which
long-term disease-free survival can be achieved. Despite this favorable prospect, even in
younger patients with relapsed AML only about 40% of the patients reach allogeneic HCT. A
number of factors contribute to this low rate of transplantation, among them moderate
activity of the salvage regimens and accumulating toxicities which prevent from
transplantation; Prospective clinical trials in this indication usually focus either on the
rate of CR achieved after a defined number of cycles of salvage therapy or on transplantation
modalities. The consequent integration of salvage therapy into a transplant strategy
accounting for the time-dependent process of donor search has not been studied so far.
The objective of this study is to evaluate the safety and efficacy of clofarabine salvage
therapy prior to allogeneic HCT.